EFCC1

Across TCGA pan-cancer cohorts, EFCC1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EFCC1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EFCC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EFCC1 expression acts as an unfavorable survival marker.

HNSC, BRCA, and SARC are the cancer types where EFCC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	42	view →
BRCA	DFS	Median	All	0.140	0.527	.002	8	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EFCC1–HNSC (OS)

Open the HNSC breakdown →